EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
NovaBay Pharmaceuticals, Inc. (NBY) had EBIT Margin of -59.70% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$9.78M |
|
$-8.61M |
|
$3.30M |
|
$6.48M |
|
$15.62M |
|
$-5.84M |
|
$-1.37M |
|
$-7.21M |
|
$-7.21M |
|
$-7.21M |
|
$-7.21M |
|
$-7.22M |
|
$-7.21M |
|
$-5.84M |
|
$-5.80M |
|
3.40M |
|
3.40M |
|
$-2.53 |
|
$-2.53 |
|
| Balance Sheet Financials | |
$1.94M |
|
$0.05M |
|
$1.49M |
|
$3.42M |
|
$2.84M |
|
-- |
|
$0.71M |
|
$3.55M |
|
$-0.14M |
|
$-0.13M |
|
$-0.13M |
|
4.88M |
|
| Cash Flow Statement Financials | |
$-5.18M |
|
$1.06M |
|
$1.50M |
|
$3.61M |
|
$0.91M |
|
$-2.70M |
|
$0.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.68 |
|
-- |
|
-- |
|
-- |
|
-4.38 |
|
66.26% |
|
-59.70% |
|
|
EBIT Margin |
-59.70% |
-59.29% |
|
-73.71% |
|
-88.01% |
|
$-5.19M |
|
-- |
|
-- |
|
-- |
|
2.86 |
|
4.31 |
|
25.14 |
|
14.52 |
|
5340.35% |
|
5589.15% |
|
-210.63% |
|
5589.15% |
|
$-0.03 |
|
$-1.53 |
|
$-1.53 |
|